Skip to content
Projects
Groups
Snippets
Help
Loading...
Help
Submit feedback
Sign in / Register
Toggle navigation
O
official
Project
Project
Details
Activity
Releases
Cycle Analytics
Repository
Repository
Files
Commits
Branches
Tags
Contributors
Graph
Compare
Charts
Issues
0
Issues
0
List
Board
Labels
Milestones
Merge Requests
0
Merge Requests
0
Wiki
Wiki
Snippets
Snippets
Members
Members
Collapse sidebar
Close sidebar
Activity
Graph
Charts
Create a new issue
Commits
Issue Boards
Open sidebar
吕祺
official
Commits
73115066
Commit
73115066
authored
Jan 18, 2023
by
吕祺
⛹🏽
Browse files
Options
Browse Files
Download
Email Patches
Plain Diff
自动文章合并|自动图片压缩
parent
54ca837d
Changes
1
Pipelines
1
Hide whitespace changes
Inline
Side-by-side
Showing
1 changed file
with
7 additions
and
0 deletions
+7
-0
newsList.md
content/newsList.md
+7
-0
No files found.
content/newsList.md
View file @
73115066
...
@@ -323,6 +323,13 @@ news:
...
@@ -323,6 +323,13 @@ news:
createDate
:
2022-11-03T16:33:03.741Z
createDate
:
2022-11-03T16:33:03.741Z
abstract
:
>-
abstract
:
>-
北京时间11月4日,中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物(股票代码:02367.HK)在港交所主板上市,成为“胶原蛋白第一股”。此前,2021年10月,巨子生物完成了自成立以来唯一一轮融资,高榕资本参与投资。
北京时间11月4日,中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物(股票代码:02367.HK)在港交所主板上市,成为“胶原蛋白第一股”。此前,2021年10月,巨子生物完成了自成立以来唯一一轮融资,高榕资本参与投资。
abstractEN: >-
On November 4, Giant Biogene (stock code: 02367.HK), a leader in China's
professional skin care product industry based on bioactive ingredients, was
listed on the main board of the HKEX, becoming the "first collagen stock".
Previously, in October 2021, Giant Biogene completed the only round of
financing since its establishment, and Gaorong Capital participated in the
investment.
content: >-
content: >-
北京时间11月4日,中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物(股票代码:02367.HK)在港交所主板上市,成为“胶原蛋白第一股”。此前,2021年10月,巨子生物完成了自成立以来唯一一轮融资,高榕资本参与投资。
北京时间11月4日,中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物(股票代码:02367.HK)在港交所主板上市,成为“胶原蛋白第一股”。此前,2021年10月,巨子生物完成了自成立以来唯一一轮融资,高榕资本参与投资。
Write
Preview
Markdown
is supported
0%
Try again
or
attach a new file
Attach a file
Cancel
You are about to add
0
people
to the discussion. Proceed with caution.
Finish editing this message first!
Cancel
Please
register
or
sign in
to comment